Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

101. Ezetimibe plus a Statin after Acute Coronary Syndromes.

Ezetimibe plus a Statin after Acute Coronary Syndromes. Ezetimibe plus a Statin after Acute Coronary Syndromes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26444740 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 8;373(15):1475-6. doi: 10.1056/NEJMc1509363#SA6. Ezetimibe plus a Statin after Acute Coronary Syndromes. , , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26444740 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments

NEJM2015 Full Text: Link to full Text with Trip Pro

102. Ezetimibe plus a Statin after Acute Coronary Syndromes.

Ezetimibe plus a Statin after Acute Coronary Syndromes. Ezetimibe plus a Statin after Acute Coronary Syndromes. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26444741 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Oct 8;373(15):1476. doi: 10.1056/NEJMc1509363#SA7. Ezetimibe plus a Statin after Acute Coronary Syndromes. , , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26444741 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments

NEJM2015 Full Text: Link to full Text with Trip Pro

103. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines

Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines 26224808 2015 09 10 2015 12 04 2016 12 03 1524-4539 132 10 2015 Sep 08 Circulation Circulation Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. 916-22 10.1161/CIRCULATIONAHA (...) .115.016846 In the general population, the majority of cardiovascular events occur in people at the low to moderate end of population risk distribution. The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol recommends consideration of statin therapy for adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5% based on traditional risk factors. Whether use of nontraditional risk markers can improve risk

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

104. Do statins increase the risk of developing diabetes?

Do statins increase the risk of developing diabetes? Do statins increase the risk of developing diabetes? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do statins increase the risk of developing diabetes? View/ Open Date 2015-04 Contributor Format Metadata Abstract Q: Do statins increase the risk of developing (...) diabetes? A: Yes. Statin therapy produces a small increase in the incidence of diabetes: one additional case per 255 patients taking statins over 4 years (strength of recommendation [SOR]: A, meta-analysis). Intensive statin therapy, compared with moderate therapy, produces an additional 2 cases of diabetes per 1000 patient years (SOR: B, meta-analysis with significant heterogeneity among trials). URI Citation Journal of Family Practice, 64(4) 2015: 245-246. Collections hosted by hosted by

Clinical Inquiries2015

105. Do statins increase the risk of developing diabetes?

Do statins increase the risk of developing diabetes? Do statins increase the risk of developing diabetes? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do statins increase the risk of developing diabetes? View/ Open Date 2015-04 Contributor Format Metadata Abstract Q: Do statins increase the risk of developing (...) diabetes? A: Yes. Statin therapy produces a small increase in the incidence of diabetes: one additional case per 255 patients taking statins over 4 years (strength of recommendation [SOR]: A, meta-analysis). Intensive statin therapy, compared with moderate therapy, produces an additional 2 cases of diabetes per 1000 patient years (SOR: B, meta-analysis with significant heterogeneity among trials). URI Citation Journal of Family Practice, 64(4) 2015: 245-246. Collections hosted by hosted by

Clinical Inquiries2015

106. Prescribing statins for patients with ACS? No need to wait

Prescribing statins for patients with ACS? No need to wait Prescribing statins for patients with ACS? No need to wait Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Prescribing statins for patients with ACS? No need to wait View/ Open Date 2014-12 Format Metadata Abstract PRACTICE CHANGER: Prescribe a high-dose statin

PURLS2015

107. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. 26039521 2015 06 18 2015 06 24 2016 12 14 1533-4406 372 25 2015 Jun 18 The New England journal of medicine N. Engl. J. Med. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. 2387-97 10.1056/NEJMoa1410489 Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption (...) were similar in the two groups. When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit. (Funded by Merck; IMPROVE-IT ClinicalTrials.gov number, NCT00202878.). Cannon Christopher P CP From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, and Harvard Medical School, Boston (C.P.C

NEJM2015

108. Comparison of Frequency of Inflammatory Bowel Disease and Noninfectious Gastroenteritis Among Statin Users Versus Nonusers

Comparison of Frequency of Inflammatory Bowel Disease and Noninfectious Gastroenteritis Among Statin Users Versus Nonusers 25784517 2015 04 29 2015 07 07 2017 03 01 1879-1913 115 10 2015 May 15 The American journal of cardiology Am. J. Cardiol. Comparison of frequency of inflammatory bowel disease and noninfectious gastroenteritis among statin users versus nonusers. 1396-401 10.1016/j.amjcard.2015.02.035 S0002-9149(15)00731-6 Conflicting data exist regarding the effects of statin therapy on (...) the prevalence of inflammatory bowel diseases. We aimed to examine the association of statin therapy with diagnoses of inflammatory bowel diseases and noninfectious gastroenteritis. This is a retrospective study using data of a military health care system from October 1, 2003, to March 1, 2012. Based on medication fills during fiscal year 2005, patients were divided into: (1) statin users (received at least 90-day supply of statin) and (2) nonusers (never received a statin). A propensity score-matched cohort

EvidenceUpdates2015

109. Statins and congenital malformations: cohort study.

Statins and congenital malformations: cohort study. OBJECTIVE: To examine the teratogenic potential of statins. DESIGN: Cohort study. SETTING: United States. PARTICIPANTS: A cohort of 886,996 completed pregnancies linked to liveborn infants of women enrolled in Medicaid from 2000 to 2007. METHODS: We examined the risk of major congenital malformations and organ specific malformations in offspring associated with maternal use of a statin in the first trimester. Propensity score based methods (...) were used to control for potential confounders, including maternal demographic characteristics, obstetric and medical conditions, and use of other drugs. RESULTS: 1152 (0.13%) women used a statin during the first trimester. In unadjusted analyses, the prevalence of malformations in the offspring of these women was 6.34% compared with 3.55% in those of women who did not use a statin in the first trimester (relative risk 1.79, 95% confidence interval 1.43 to 2.23). Controlling for confounders

BMJ2015

110. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial 25687353 2015 05 15 2016 02 18 2017 02 20 1522-9645 36 19 2015 May 14 European heart journal Eur. Heart J. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO (...) II randomized controlled trial. 1186-94 10.1093/eurheartj/ehv028 To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9, compared with ezetimibe, as add-on therapy to maximally tolerated statin therapy in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia. COMBO II is a double-blind, double-dummy, active-controlled, parallel-group, 104

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

111. Pleiotropic effects of statins in hypercholesterolaemia: a prospective observational study using a lipoproteomic based approach.

Pleiotropic effects of statins in hypercholesterolaemia: a prospective observational study using a lipoproteomic based approach. BACKGROUND: The benefit of statins in the prevention of cardiovascular disease is well founded, derived from their lipid lowering and pleiotropic effects. The concept of lipoproteins as lipid transporters has evolved to encompass functions in coagulation, inflammation, and redox reactions due to their unique protein cargo. The aim of this study was to determine (...) the effect of statin therapy on lipoproteins and their protein cargo by use of an unbiased bottom-up proteomics approach in people with hypercholesterolaemia. METHODS: 11 people fulfilling the inclusion criteria were recruited into this UK-based single centre prospective observational study. They were started on statins for primary prevention. Blood was withdrawn at baseline and after a minimum of 2 months of statin therapy. Plasma was co-incubated with a lipoaffinity resin. Isolated proteins were

Lancet2015

112. Statins for age-related macular degeneration.

Statins for age-related macular degeneration. BACKGROUND: Age-related macular degeneration (AMD) is a progressive late onset disorder of the macula affecting central vision. Age-related macular degeneration is the leading cause of blindness in people over 65 years in industrialized countries. Recent epidemiologic, genetic, and pathological evidence has shown AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective effects in AMD (...) . OBJECTIVES: The objective of this review was to examine the effectiveness of statins compared with other treatments, no treatment, or placebo in delaying the onset and progression of AMD. SEARCH METHODS: We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 6), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to June 2014), EMBASE (January 1980 to June 2014), Latin American and Caribbean

Cochrane2015

113. Systematic review with meta analysis: With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes

Systematic review with meta analysis: With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes Article Text Therapeutics/Prevention Systematic review with meta analysis With statin co-administration, drugs designed to increase HDL have no impact

Evidence-Based Medicine (Requires free registration)2015

114. Cost-effectiveness: Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention

Cost-effectiveness: Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention Article Text Economic analysis Cost-effectiveness Current 10-year atherosclerotic

Evidence-Based Medicine (Requires free registration)2015

115. Cohort study: Risk of new-onset diabetes with statin use should not be overemphasised

Cohort study: Risk of new-onset diabetes with statin use should not be overemphasised Risk of new-onset diabetes with statin use should not be overemphasised | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risk of new-onset diabetes with statin use should not be overemphasised Article Text Aetiology/Harm Cohort study Risk of new-onset diabetes with statin use should not be overemphasised Chern-En Chiang , Kang-Ling Wang Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Mansi I , Frei CR , Wang CP , et al

Evidence-Based Medicine (Requires free registration)2015

116. Statins for primary prevention of venous thromboembolism.

Statins for primary prevention of venous thromboembolism. BACKGROUND: Venous thromboembolism (VTE) is common in clinical practice. The efficacy of statins in the primary prevention of VTE remains unproven. This is an update of the review first published in 2011. OBJECTIVES: To assess the efficacy of statins in the primary prevention of VTE. SEARCH METHODS: For this update the Cochrane Peripheral Vascular Diseases (PVD) Group Trials Search Co-ordinator searched the Specialised Register (last (...) searched February 2014) and CENTRAL (2014, Issue 1). SELECTION CRITERIA: Randomised controlled trials (RCTs) that assessed statins in the primary prevention of VTE were considered. The outcomes we evaluated were the rates of VTE, cardiovascular and cerebrovascular events, death and adverse events. Two authors (L Li, JH Tian) independently selected RCTs against the inclusion criteria. Disagreements were resolved by discussion with a third author (KH Yang). DATA COLLECTION AND ANALYSIS: Data extraction

Cochrane2014

117. Statins: proven and associated harms

Statins: proven and associated harms [89] Statins: proven and associated harms | Therapeutics Initiative Independent Healthcare Evidence > > [89] Statins: proven and associated harms (Jul-Sept 2003) concluded that “Statins provide a cardiovascular and total mortality benefit for patients with clinically evident occlusive vascular disease (secondary prevention)” and (Mar-Apr 2010) concluded that “Statins do not have a net health benefit in primary prevention populations”, because they reduce (...) coronary heart disease (CHD) serious adverse events (SAEs), but have no effect on total SAEs. This suggests that there are unidentified SAEs caused by statins that counterbalance the reduction in CHD SAEs. Concerns about SAEs related to HMG-CoA reductase inhibitors (statins) were first raised in 2001, when cerivastatin was withdrawn from the market after being linked to over 100 deaths from muscle damage occurring at a rate much higher than other statins. This Letter examines proven and associated

Therapeutics Letter2014

118. Further Insight Into the Cardiovascular Risk Calculator: The Roles of Statins, Revascularizations, and Underascertainment in the Women's Health Study

Further Insight Into the Cardiovascular Risk Calculator: The Roles of Statins, Revascularizations, and Underascertainment in the Women's Health Study 25285455 2014 12 02 2015 02 25 2016 12 03 2168-6114 174 12 2014 Dec JAMA internal medicine JAMA Intern Med Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. 1964-71 10.1001/jamainternmed.2014.5336 While the pooled cohort equations from the recent (...) American College of Cardiology/American Heart Association (ACC/AHA) Guideline on the Assessment of Cardiovascular Risk have overestimated cardiovascular risk in multiple external cohorts, the reasons for the discrepancy are unclear. To determine whether increased use of statins over time, incident coronary revascularization procedures, or underascertainment of vascular events explain overestimation of risk in a more contemporary population. The Women's Health Study (WHS) is a nationwide cohort of US

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

119. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study.

Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. BACKGROUND: Statins are effective in preventing cardiovascular events, but patients do not fully adhere to them. OBJECTIVE: To determine whether patients are more adherent to generic statins versus brand-name statins (lovastatin, pravastatin, or simvastatin) and whether greater adherence improves health outcomes. DESIGN: Observational, propensity score-matched, new-user cohort study. SETTING: Linked (...) electronic data from medical and pharmacy claims. PARTICIPANTS: Medicare beneficiaries aged 65 years or older with prescription drug coverage between 2006 and 2008. INTERVENTION: Initiation of a generic or brand-name statin. MEASUREMENTS: Adherence to statin therapy (measured as the proportion of days covered [PDC] up to 1 year) and a composite outcome comprising hospitalization for an acute coronary syndrome or stroke and all-cause mortality. Hazard ratios (HRs) and absolute rate differences were

Annals of Internal Medicine2014

120. Non-cardiovascular effects associated with statins.

Non-cardiovascular effects associated with statins. Statins form the pharmacologic cornerstone of the primary and secondary prevention of atherosclerotic cardiovascular disease. In addition to beneficial cardiovascular effects, statins seem to have multiple non-cardiovascular effects. Although early concerns about statin induced hepatotoxicity and cancer have subsided owing to reassuring evidence, two of the most common concerns that clinicians have are myopathy and diabetes. Randomized (...) controlled trials suggest that statins are associated with a modest increase in the risk of myositis but not the risk of myalgia. Severe myopathy (rhabdomyolysis) is rare and often linked to a statin regimen that is no longer recommended (simvastatin 80 mg). Randomized controlled trials and meta-analyses suggest an increase in the risk of diabetes with statins, particularly with higher intensity regimens in people with two or more components of the metabolic syndrome. Other non-cardiovascular effects

BMJ2014